Novo Nordisk A/S
Stocks making the biggest moves midday: Tesla, Novo Nordisk, Hims & Hers, Northern Trust, Fiserv and more
Check out the companies making headlines in midday trading: Tesla — Shares jumped more than 10% after Tesla rolled out its robotaxi service in Austin, Texas, over the weekend. Wedbush analyst Dan Ives said a ride in the taxi exceeded his expectations . However, some analysts were more reserved. Northern Trust — Shares rose 7% […]
Read More
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images Novo Nordisk on Monday said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company’s sales […]
Read More
Stocks making the biggest moves premarket: Tesla, Northern Trust, DoorDash, Northrop Grumman, Exxon Mobil and more
Check out the companies making headlines before the bell. Northern Trust – Shares rose more than 6% after the Wall Street Journal, citing people familiar with the matter, reported that Bank of New York Mellon approached Northern Trust last week to convey interest in a merger between the two rivals. The report also said that […]
Read More
Where can equity investors hide as Israel and Iran take aim at each other?
As equity markets broadly declined after Israel and Iran took aim at each other – some sectors and stocks are bucking the trend. The attack, which reportedly killed senior Iranian military and scientific figures, prompted an immediate flight to safety in financial markets. Brent crude , the international oil benchmark, jumped 7% to $78.50 a […]
Read More
Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
Weight loss syringes of the brands “Wegovy”, “Ozempic” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo […]
Read More
A ‘perfect storm’ has set this sector up to benefit if Trump’s tariffs go ahead, Bank of America says
U.S. President Donald Trump’s tariffs regime has rocked international markets in recent weeks, sparking massive selloffs and rallies in stocks across the globe. Certain tariff-sensitive stocks, such as those in the autos, mining and pharmaceuticals sectors, have seen particularly volatile trade. In a Wednesday ruling , however, the U.S. Court of International Trade blocked the […]
Read More
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Only half of health insurer Cigna‘s clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company’s pharmacy benefits unit Evernorth has reached a deal with […]
Read More
Novo Nordisk’s future in doubt after Wegovy maker’s ‘surprise’ CEO ouster
Novo Nordisk’s ousting of longtime CEO Lars Fruergaard Jørgensen bemused analysts, with many questioning the future of the Wegovy obesity drug maker. Source
Read More
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that […]
Read More
This money manager won’t follow Warren Buffett’s path with these two stocks Berkshire’s buying
New regulatory filings showed that Warren Buffett ‘s Berkshire Hathaway doubled its position in beer and wine producer Constellation Brands last quarter. But at least one investor doesn’t agree with the “Oracle of Omaha’s” investment. Main Street Research’s Chief Investment Officer James Demmert joined CNBC’s ” Power Lunch ” on Friday to offer his take […]
Read More